Compare Honest Company Inc (HNST) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Natera Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $557.34M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 102.3× Honest Company Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Natera Inc. Common Stock for 0 Days on average.
| HNST | NTRA | |
|---|---|---|
Market Cap | $557.34M | $57.03B |
Volume | 749,013 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $425.64 |
52-Week Low | $2.10 | $179.42 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $460.95M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, down 1.74% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.04 EPS versus $0.00926 expected, though revenue declined year-over-year to $371.32M in 2025. Recent news highlights institutional buying from BlackRock and Deutsche Bank, while Seeking Alpha notes the company's turnaround progress through strategic exits and cost reductions.
The stock faces headwinds from negative profitability metrics (-3.56% net margin, -6.87% ROE) and elevated P/E of 48.83, but analyst consensus targets $5.30 with 30% buy ratings. Key risks include continued margin pressure and competitive threats in personal care, while potential upside hinges on sustained operational improvements and market share gains.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
